AU776824B2
(en)
|
1999-04-22 |
2004-09-23 |
Unilever Plc |
Inhibition of viral infection using monovalent antigen-binding proteins
|
BR0012711A
(pt)
|
1999-07-27 |
2002-04-09 |
Unilever Nv |
Composição detergente enzimática, e, processos para aumentar a atividade e / ou a estabilidade de uma oxidorredutase dependente de co-fator e para branquear manchas presentes em tecidos
|
DK1233987T3
(da)
*
|
1999-11-29 |
2009-09-28 |
Bac Ip B V |
Immobiliserede enkelt-domæne antigenbindende molekyler
|
BR0016570A
(pt)
|
1999-12-22 |
2002-10-01 |
Unilever Nv |
Proteìna de fusão, composição detergente, e, processo para fornecer um agente de benefìcio a um tecido
|
ATE307871T1
(de)
|
1999-12-22 |
2005-11-15 |
Unilever Nv |
Verfahren zur behandlung von gewebe
|
ATE266761T1
(de)
|
1999-12-22 |
2004-05-15 |
Unilever Nv |
Verfahren und einrichtung zur behandlung von textilwaren
|
EP1242572A2
(en)
|
1999-12-22 |
2002-09-25 |
Unilever N.V. |
Method of delivering a benefit agent
|
BR0016662A
(pt)
*
|
1999-12-23 |
2002-09-03 |
Unilever Nv |
Composição detergente de alvejamento enzimática, e, processo para alvejamento de manchas presentes em tecidos
|
PL357939A1
(en)
*
|
2000-04-11 |
2004-08-09 |
Genentech, Inc. |
Multivalent antibodies and uses therefor
|
US20060073141A1
(en)
*
|
2001-06-28 |
2006-04-06 |
Domantis Limited |
Compositions and methods for treating inflammatory disorders
|
JP2005289809A
(ja)
*
|
2001-10-24 |
2005-10-20 |
Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) |
突然変異重鎖抗体
|
JP4323317B2
(ja)
*
|
2001-12-21 |
2009-09-02 |
フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー(ヴェーイーベー・ヴェーゼットウェー) |
可変領域配列のクローニング方法
|
ATE328906T1
(de)
|
2002-06-28 |
2006-06-15 |
Domantis Ltd |
Dual-specifische liganden mit erhöhter halbwertszeit
|
US20060002935A1
(en)
|
2002-06-28 |
2006-01-05 |
Domantis Limited |
Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
|
US7696320B2
(en)
|
2004-08-24 |
2010-04-13 |
Domantis Limited |
Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
|
US9321832B2
(en)
|
2002-06-28 |
2016-04-26 |
Domantis Limited |
Ligand
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
JP4836451B2
(ja)
|
2002-07-18 |
2011-12-14 |
メルス ベー ヴェー |
抗体混合物の組換え生産
|
EP1527346B1
(en)
|
2002-08-07 |
2011-06-08 |
Ablynx N.V. |
Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
|
US20060034833A1
(en)
*
|
2002-11-08 |
2006-02-16 |
Els Beirnaert |
Single domain antibodies directed against interferron-gamma and uses therefor
|
ES2655912T3
(es)
*
|
2002-11-08 |
2018-02-22 |
Ablynx N.V. |
Anticuerpos de dominio simple dirigidos contra factor de necrosis tumoral-alfa y usos para los mismos
|
US20100003253A1
(en)
*
|
2002-11-08 |
2010-01-07 |
Ablynx N.V. |
Single domain antibodies directed against epidermal growth factor receptor and uses therefor
|
EP1558647B1
(en)
*
|
2002-11-08 |
2015-06-10 |
Ablynx N.V. |
Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
|
US20060034845A1
(en)
*
|
2002-11-08 |
2006-02-16 |
Karen Silence |
Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
|
US9320792B2
(en)
|
2002-11-08 |
2016-04-26 |
Ablynx N.V. |
Pulmonary administration of immunoglobulin single variable domains and constructs thereof
|
EP3299393A1
(en)
*
|
2002-11-08 |
2018-03-28 |
Ablynx N.V. |
Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
|
US6974860B2
(en)
|
2002-12-30 |
2005-12-13 |
Kimberly-Clark Worldwide, Inc. |
Target recognizing binding agents
|
RU2357974C2
(ru)
|
2003-01-10 |
2009-06-10 |
Аблинкс Н.В. |
Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
WO2004106375A1
(en)
|
2003-05-30 |
2004-12-09 |
Merus Biopharmaceuticals B.V. I.O. |
Fab library for the preparation of anti vegf and anti rabies virus fabs
|
ATE485307T1
(de)
*
|
2003-11-07 |
2010-11-15 |
Ablynx Nv |
Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
|
AU2005205412B2
(en)
*
|
2004-01-20 |
2011-08-11 |
Merus N.V. |
Mixtures of binding proteins
|
CN1954214B
(zh)
*
|
2004-03-30 |
2012-07-04 |
通用电气医疗集团生物科学公司 |
侧流格式、材料和方法
|
WO2005113604A2
(en)
*
|
2004-05-14 |
2005-12-01 |
Hematech, Llc |
Methods for immunoglobulin purification
|
US7563443B2
(en)
|
2004-09-17 |
2009-07-21 |
Domantis Limited |
Monovalent anti-CD40L antibody polypeptides and compositions thereof
|
CN101724071A
(zh)
|
2004-10-08 |
2010-06-09 |
杜门蒂斯有限公司 |
抗肿瘤坏死因子受体1的单域抗体及其使用方法
|
WO2006059904A1
(en)
*
|
2004-12-02 |
2006-06-08 |
Unilever N.V. |
Method for affinity purification
|
FR2879605B1
(fr)
|
2004-12-16 |
2008-10-17 |
Centre Nat Rech Scient Cnrse |
Production de formats d'anticorps et applications immunologiques de ces formats
|
PL1836500T3
(pl)
*
|
2005-01-14 |
2010-12-31 |
Ablynx Nv |
Sposoby i testy do rozróżniania między różnymi postaciami chorób i zaburzeń cechujących się małopłytkowością i/lub samoistną interakcją między czynnikiem von Willebranda (vWF) a płytkami krwi
|
PL1888641T3
(pl)
|
2005-05-18 |
2012-05-31 |
Ablynx Nv |
Białka wiążące albuminę surowicy
|
NZ563392A
(en)
|
2005-05-20 |
2009-12-24 |
Ablynx Nv |
Improved Nanobodies(TM) for the treatment of aggregation-mediated disorders
|
DE102005023617A1
(de)
*
|
2005-05-21 |
2006-11-23 |
Aspre Ag |
Verfahren zum Mischen von Farben in einem Display
|
CA2622968A1
(en)
*
|
2005-09-23 |
2007-03-29 |
Academisch Ziekenhuis Leiden |
Vhh for the diagnosis, prevention and treatment of diseases associated with protein aggregates
|
US20070269422A1
(en)
*
|
2006-05-17 |
2007-11-22 |
Ablynx N.V. |
Serum albumin binding proteins with long half-lives
|
GB0621513D0
(en)
|
2006-10-30 |
2006-12-06 |
Domantis Ltd |
Novel polypeptides and uses thereof
|
EP2115004A2
(en)
|
2006-12-19 |
2009-11-11 |
Ablynx N.V. |
Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
|
EP2514767A1
(en)
|
2006-12-19 |
2012-10-24 |
Ablynx N.V. |
Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
|
CN101842387B
(zh)
|
2007-09-26 |
2014-05-07 |
Ucb医药有限公司 |
双特异性抗体融合物
|
EP2252303A2
(en)
*
|
2008-03-21 |
2010-11-24 |
Ablynx NV |
Von willebrand factor specific binders and methods of use therefor
|
CN102056945A
(zh)
|
2008-04-07 |
2011-05-11 |
埃博灵克斯股份有限公司 |
针对Notch途径的单可变结构域
|
CN102076355B
(zh)
|
2008-04-29 |
2014-05-07 |
Abbvie公司 |
双重可变结构域免疫球蛋白及其用途
|
EP3002299A1
(en)
|
2008-06-03 |
2016-04-06 |
AbbVie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
US9109026B2
(en)
|
2008-06-03 |
2015-08-18 |
Abbvie, Inc. |
Dual variable domain immunoglobulins and uses thereof
|
KR20110031369A
(ko)
|
2008-07-08 |
2011-03-25 |
아보트 러보러터리즈 |
프로스타글란딘 e2 이원 가변 도메인 면역글로불린 및 이의 용도
|
US20100136584A1
(en)
*
|
2008-09-22 |
2010-06-03 |
Icb International, Inc. |
Methods for using antibodies and analogs thereof
|
CN105601745B
(zh)
*
|
2008-09-26 |
2020-09-08 |
Ucb医药有限公司 |
生物产品
|
US10118962B2
(en)
|
2008-10-29 |
2018-11-06 |
Ablynx N.V. |
Methods for purification of single domain antigen binding molecules
|
EP4104821A1
(en)
|
2008-10-29 |
2022-12-21 |
Ablynx N.V. |
Formulations of single domain antigen binding molecules
|
CA2747644C
(en)
|
2008-12-19 |
2023-01-24 |
Ablynx N.V. |
Method for generation of immunoglobulin sequences
|
AU2010205627B2
(en)
|
2009-01-14 |
2015-04-02 |
Ablynx Nv |
Pulmonary administration of immunoglobulin single variable domains and constructs thereof
|
WO2010100135A1
(en)
|
2009-03-05 |
2010-09-10 |
Ablynx N.V. |
Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
|
GB0905023D0
(en)
|
2009-03-24 |
2009-05-06 |
Univ Erasmus Medical Ct |
Binding molecules
|
ES2864956T3
(es)
|
2009-04-30 |
2021-10-14 |
Ablynx Nv |
Procedimiento para la producción de anticuerpos de dominio
|
HUE051430T2
(hu)
|
2009-07-10 |
2021-03-01 |
Ablynx Nv |
Eljárás variábilis domének elõállítására
|
NZ598929A
(en)
|
2009-09-01 |
2014-05-30 |
Abbvie Inc |
Dual variable domain immunoglobulins and uses thereof
|
PL3438126T3
(pl)
|
2009-09-03 |
2021-03-08 |
Ablynx N.V. |
Stabilne formulacje polipeptydów i ich zastosowanie
|
WO2011045079A1
(en)
|
2009-10-15 |
2011-04-21 |
Intercell Ag |
Hepatitis b virus specific human antibodies
|
CN102666875A
(zh)
|
2009-10-15 |
2012-09-12 |
雅培制药有限公司 |
双重可变结构域免疫球蛋白及其用途
|
EP2489724A4
(en)
*
|
2009-10-16 |
2013-05-01 |
Kaneka Corp |
HANSENULA POLYMORPHA SUITABLE FOR ANTIBODY PRODUCTION, ANTIBODY MANUFACTURING METHODS THEREFOR AND ANTIBODIES MANUFACTURED IN THIS PROCEDURE
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
WO2011073180A1
(en)
|
2009-12-14 |
2011-06-23 |
Ablynx N.V. |
Single variable domain antibodies against ox40l, constructs and therapeutic use
|
WO2011083141A2
(en)
|
2010-01-08 |
2011-07-14 |
Ablynx Nv |
Method for generation of immunoglobulin sequences by using lipoprotein particles
|
US9120855B2
(en)
|
2010-02-10 |
2015-09-01 |
Novartis Ag |
Biologic compounds directed against death receptor 5
|
CN105380904A
(zh)
|
2010-02-11 |
2016-03-09 |
埃博灵克斯股份有限公司 |
用于制备气雾剂的方法和组合物
|
WO2011098518A2
(en)
|
2010-02-11 |
2011-08-18 |
Ablynx Nv |
Delivery of immunoglobulin variable domains and constructs thereof
|
RU2012149227A
(ru)
|
2010-05-20 |
2014-06-27 |
Аблинкс Нв |
Биологические материалы, относящиеся к her3
|
WO2011161263A1
(en)
|
2010-06-25 |
2011-12-29 |
Ablynx Nv |
Pharmaceutical compositions for cutaneous administration
|
BR112013002578A2
(pt)
|
2010-08-03 |
2019-05-14 |
Abbvie Inc. |
imunoglobinas de domínio variável duplo e usos das mesmas
|
AU2011293253B2
(en)
|
2010-08-26 |
2014-12-11 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
WO2012042026A1
(en)
|
2010-09-30 |
2012-04-05 |
Ablynx Nv |
Biological materials related to c-met
|
PL2632946T3
(pl)
|
2010-10-29 |
2018-06-29 |
Ablynx N.V. |
Sposób wytwarzania pojedynczych domen zmiennych immunoglobulin
|
EA202092589A3
(ru)
|
2010-11-08 |
2021-06-30 |
Аблинкс Н.В. |
Cxcr2-связывающие полипептиды
|
US9468679B2
(en)
|
2011-03-28 |
2016-10-18 |
Ablynx N.V. |
Method for producing solid formulations comprising immunoglobulin single variable domains
|
UA117218C2
(uk)
|
2011-05-05 |
2018-07-10 |
Мерк Патент Гмбх |
Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
|
EP3590950A1
(en)
|
2011-05-09 |
2020-01-08 |
Ablynx NV |
Method for the production of immunoglobulin single varible domains
|
CA2839779C
(en)
|
2011-06-23 |
2020-10-06 |
Ablynx Nv |
Serum albumin binding proteins
|
DK2747782T3
(en)
|
2011-09-23 |
2018-04-23 |
Ablynx Nv |
Long-term inhibition of interleukin-6-mediated signal transmission
|
WO2013045707A2
(en)
|
2011-09-30 |
2013-04-04 |
Ablynx Nv |
Biological materials related to c-met
|
WO2013081143A1
(ja)
|
2011-11-30 |
2013-06-06 |
中外製薬株式会社 |
免疫複合体を形成する細胞内への運搬体(キャリア)を含む医薬
|
TW201333035A
(zh)
|
2011-12-30 |
2013-08-16 |
Abbvie Inc |
針對il-13及/或il-17之雙特異性結合蛋白
|
PT2838917T
(pt)
|
2012-04-20 |
2019-09-12 |
Merus Nv |
Métodos e meios para a produção de moléculas similares a ig heterodiméricas
|
US9328174B2
(en)
|
2012-05-09 |
2016-05-03 |
Novartis Ag |
Chemokine receptor binding polypeptides
|
CA2874721A1
(en)
|
2012-05-30 |
2013-12-05 |
Tomoyuki Igawa |
Target tissue-specific antigen-binding molecule
|
US11339208B1
(en)
|
2012-05-31 |
2022-05-24 |
United States Of America As Represented By The Secretary Of The Air Force |
Camelidae single-domain antibodies against Yersinia pestis and methods of use
|
MY194330A
(en)
|
2012-11-01 |
2022-11-28 |
Abbvie Inc |
Anti-dll4/vegf dual variable domain immunoglobulin and uses thereof
|
CN105324396A
(zh)
|
2013-03-15 |
2016-02-10 |
艾伯维公司 |
针对IL-1β和/或IL-17的双重特异性结合蛋白
|
WO2014163101A1
(ja)
|
2013-04-02 |
2014-10-09 |
中外製薬株式会社 |
Fc領域改変体
|
NL1040254C2
(en)
|
2013-05-17 |
2014-11-24 |
Ablynx Nv |
Stable formulations of immunoglobulin single variable domains and uses thereof.
|
KR20220142539A
(ko)
|
2013-12-04 |
2022-10-21 |
추가이 세이야쿠 가부시키가이샤 |
화합물의 농도에 따라 항원 결합능이 변화되는 항원 결합 분자 및 그의 라이브러리
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
TWI777174B
(zh)
|
2014-03-14 |
2022-09-11 |
瑞士商諾華公司 |
針對lag-3之抗體分子及其用途
|
EP3593812A3
(en)
|
2014-03-15 |
2020-05-27 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor
|
NL2013661B1
(en)
|
2014-10-21 |
2016-10-05 |
Ablynx Nv |
KV1.3 Binding immunoglobulins.
|
MX2016017393A
(es)
|
2014-07-01 |
2017-09-05 |
Pfizer |
Diacuerpos heterodimericos biespecificos y sus usos.
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のmTOR阻害剤とCARの組み合わせ
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
MX2017001011A
(es)
|
2014-07-21 |
2018-05-28 |
Novartis Ag |
Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
|
CN107109419B
(zh)
|
2014-07-21 |
2020-12-22 |
诺华股份有限公司 |
使用cd33嵌合抗原受体治疗癌症
|
US20170209492A1
(en)
|
2014-07-31 |
2017-07-27 |
Novartis Ag |
Subset-optimized chimeric antigen receptor-containing t-cells
|
WO2016025880A1
(en)
|
2014-08-14 |
2016-02-18 |
Novartis Ag |
Treatment of cancer using gfr alpha-4 chimeric antigen receptor
|
SG11201700770PA
(en)
|
2014-08-19 |
2017-03-30 |
Novartis Ag |
Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
|
US10577417B2
(en)
|
2014-09-17 |
2020-03-03 |
Novartis Ag |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
CN114920840A
(zh)
|
2014-10-14 |
2022-08-19 |
诺华股份有限公司 |
针对pd-l1的抗体分子及其用途
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
PT3233910T
(pt)
|
2014-12-19 |
2020-03-17 |
Ablynx Nv |
Dímeros de nanocorpos ligados a cisteína
|
AU2016239948B2
(en)
|
2015-03-31 |
2022-03-17 |
Sorriso Pharmaceuticals, Inc. |
Polypeptides
|
EP3277316A1
(en)
|
2015-04-02 |
2018-02-07 |
Ablynx N.V. |
Bispecific cxcr4-cd-4 polypeptides with potent anti-hiv activity
|
MX2017012939A
(es)
|
2015-04-08 |
2018-05-22 |
Novartis Ag |
Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
CN107847559B
(zh)
|
2015-05-13 |
2022-07-01 |
埃博灵克斯股份有限公司 |
基于cd3反应性的t细胞募集多肽
|
ES2754427T3
(es)
|
2015-05-13 |
2020-04-17 |
Ablynx Nv |
Polipéptidos de reclutamiento de células T basados en la reactividad de TCR alfa/beta
|
MX2017014908A
(es)
|
2015-05-21 |
2018-08-15 |
Harpoon Therapeutics Inc |
Proteinas de union triespecificas y metodos de uso.
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
EP3878465A1
(en)
|
2015-07-29 |
2021-09-15 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
EP3964528A1
(en)
|
2015-07-29 |
2022-03-09 |
Novartis AG |
Combination therapies comprising antibody molecules to lag-3
|
NO2768984T3
(pt)
|
2015-11-12 |
2018-06-09 |
|
|
CN115925919A
(zh)
|
2015-11-13 |
2023-04-07 |
埃博灵克斯股份有限公司 |
改进的血清白蛋白结合免疫球蛋白可变结构域
|
TW202216787A
(zh)
|
2015-11-18 |
2022-05-01 |
美商默沙東藥廠 |
Pd1及/或 lag3結合劑
|
UA125337C2
(uk)
|
2015-11-18 |
2022-02-23 |
Мерк Шарп І Доум Корп. |
Ctla4-зв'язувальні речовини
|
CN108473564B
(zh)
|
2015-11-18 |
2022-04-08 |
埃博灵克斯股份有限公司 |
改进的血清白蛋白结合剂
|
RU2018122255A
(ru)
|
2015-11-27 |
2019-12-19 |
Аблинкс Нв |
Полипептиды, ингибирующие cd40l
|
AU2016369623A1
(en)
|
2015-12-17 |
2018-06-28 |
Novartis Ag |
Combination of c-Met inhibitor with antibody molecule to PD-1 and uses thereof
|
AU2016369537B2
(en)
|
2015-12-17 |
2024-03-14 |
Novartis Ag |
Antibody molecules to PD-1 and uses thereof
|
ES2847155T3
(es)
|
2016-01-21 |
2021-08-02 |
Novartis Ag |
Moléculas multiespecíficas que fijan como objetivo CLL-1
|
WO2017149515A1
(en)
|
2016-03-04 |
2017-09-08 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
US11549099B2
(en)
|
2016-03-23 |
2023-01-10 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
SG11201809041TA
(en)
|
2016-04-15 |
2018-11-29 |
Novartis Ag |
Compositions and methods for selective protein expression
|
EP3452505A1
(en)
|
2016-05-02 |
2019-03-13 |
Ablynx NV |
Treatment of rsv infection
|
SG11201810331YA
(en)
|
2016-05-20 |
2018-12-28 |
Harpoon Therapeutics Inc |
Single chain variable fragment cd3 binding proteins
|
KR102530742B1
(ko)
|
2016-05-20 |
2023-05-09 |
하푼 테라퓨틱스, 인크. |
단일 도메인 혈청 알부민 결합 단백질
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
US20210177896A1
(en)
|
2016-06-02 |
2021-06-17 |
Novartis Ag |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
WO2018007442A1
(en)
|
2016-07-06 |
2018-01-11 |
Ablynx N.V. |
Treatment of il-6r related diseases
|
EP3484455A2
(en)
|
2016-07-15 |
2019-05-22 |
Novartis AG |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
CN118021943A
(zh)
|
2016-07-28 |
2024-05-14 |
诺华股份有限公司 |
嵌合抗原受体和pd-1抑制剂的组合疗法
|
EP3490590A2
(en)
|
2016-08-01 |
2019-06-05 |
Novartis AG |
Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
|
WO2018029182A1
(en)
|
2016-08-08 |
2018-02-15 |
Ablynx N.V. |
Il-6r single variable domain antibodies for treatment of il-6r related diseases
|
US11098113B2
(en)
|
2016-09-15 |
2021-08-24 |
Vib Vzw |
Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
|
WO2018060453A1
(en)
|
2016-09-30 |
2018-04-05 |
Vhsquared Limited |
Compositions
|
CN117866991A
(zh)
|
2016-10-07 |
2024-04-12 |
诺华股份有限公司 |
用于治疗癌症的嵌合抗原受体
|
JP7222888B2
(ja)
|
2016-11-16 |
2023-02-15 |
アブリンクス エン.ヴェー. |
Cd123及びtcrアルファ/ベータに結合することが可能なt細胞動員ポリペプチド
|
EP3544629A4
(en)
|
2016-11-23 |
2020-06-17 |
Harpoon Therapeutics, Inc. |
TRISPECIFIC PROTEINS CIBLANG PSMA AND METHODS OF USE
|
KR102275008B1
(ko)
|
2016-11-23 |
2021-07-13 |
하푼 테라퓨틱스, 인크. |
전립선 특이 막 항원 결합 단백질
|
WO2018099968A1
(en)
|
2016-11-29 |
2018-06-07 |
Ablynx N.V. |
Treatment of infection by respiratory syncytial virus (rsv)
|
CN110049997B
(zh)
|
2016-12-07 |
2023-09-22 |
埃博灵克斯股份有限公司 |
改进的血清白蛋白结合免疫球蛋白单可变结构域
|
JP7300385B2
(ja)
|
2017-01-17 |
2023-06-29 |
アブリンクス エン.ヴェー. |
改善された血清アルブミン結合剤
|
CN117285623A
(zh)
|
2017-01-17 |
2023-12-26 |
埃博灵克斯股份有限公司 |
改进的血清白蛋白结合物
|
US11535662B2
(en)
|
2017-01-26 |
2022-12-27 |
Novartis Ag |
CD28 compositions and methods for chimeric antigen receptor therapy
|
EP3589647A1
(en)
|
2017-02-28 |
2020-01-08 |
Novartis AG |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
US11535668B2
(en)
|
2017-02-28 |
2022-12-27 |
Harpoon Therapeutics, Inc. |
Inducible monovalent antigen binding protein
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
WO2018201051A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
CN115028727A
(zh)
|
2017-05-12 |
2022-09-09 |
哈普恩治疗公司 |
靶向msln的三特异性蛋白质及使用方法
|
AU2018265856B2
(en)
|
2017-05-12 |
2023-04-27 |
Harpoon Therapeutics, Inc. |
Mesothelin binding proteins
|
US20200190216A1
(en)
|
2017-06-02 |
2020-06-18 |
Merck Patent Gmbh |
Mmp13 binding immunoglobulins
|
AU2018277310A1
(en)
|
2017-06-02 |
2019-12-12 |
Ablynx Nv |
Aggrecan binding immunoglobulins
|
EP3630847A1
(en)
|
2017-06-02 |
2020-04-08 |
Merck Patent GmbH |
Adamts binding immunoglobulins
|
TWI826376B
(zh)
|
2017-06-02 |
2023-12-21 |
德商麥克專利有限公司 |
與adamts5、mmp13及聚集蛋白聚醣結合的多肽
|
CN110785187B
(zh)
|
2017-06-22 |
2024-04-05 |
诺华股份有限公司 |
针对cd73的抗体分子及其用途
|
EP3645037A1
(en)
|
2017-06-27 |
2020-05-06 |
Novartis AG |
Dosage regimens for anti-tim-3 antibodies and uses thereof
|
AU2018301393A1
(en)
|
2017-07-11 |
2020-02-06 |
Compass Therapeutics Llc |
Agonist antibodies that bind human CD137 and uses thereof
|
JP2020532285A
(ja)
|
2017-07-11 |
2020-11-12 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
補体成分c5または血清アルブミンと結合するポリペプチドおよびその融合タンパク質
|
US11155607B2
(en)
|
2017-07-19 |
2021-10-26 |
Vib Vzw |
Serum albumin binding agents
|
JP2020527572A
(ja)
|
2017-07-20 |
2020-09-10 |
ノバルティス アーゲー |
抗lag−3抗体の投薬量レジメンおよびその使用
|
BR112020007249B1
(pt)
|
2017-10-13 |
2022-11-22 |
Harpoon Therapeutics, Inc |
Roteína de ligação a antígeno de maturação de célula b, proteína de ligação multiespecífica e uso das referidas proteínas
|
CN111630070A
(zh)
|
2017-10-13 |
2020-09-04 |
哈普恩治疗公司 |
三特异性蛋白质及使用方法
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
AU2018368731A1
(en)
|
2017-11-16 |
2020-05-14 |
Novartis Ag |
Combination therapies
|
US11851497B2
(en)
|
2017-11-20 |
2023-12-26 |
Compass Therapeutics Llc |
CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
AU2019215031A1
(en)
|
2018-01-31 |
2020-08-20 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
US20210047405A1
(en)
|
2018-04-27 |
2021-02-18 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
EP3797120A1
(en)
|
2018-05-21 |
2021-03-31 |
Compass Therapeutics LLC |
Compositions and methods for enhancing the killing of target cells by nk cells
|
EP3801769A1
(en)
|
2018-05-25 |
2021-04-14 |
Novartis AG |
Combination therapy with chimeric antigen receptor (car) therapies
|
US20210214459A1
(en)
|
2018-05-31 |
2021-07-15 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
CN112203725A
(zh)
|
2018-06-13 |
2021-01-08 |
诺华股份有限公司 |
Bcma嵌合抗原受体及其用途
|
CA3104295A1
(en)
|
2018-06-19 |
2019-12-26 |
Atarga, Llc |
Antibody molecules to complement component 5 and uses thereof
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
CA3114038A1
(en)
|
2018-09-25 |
2020-04-02 |
Harpoon Therapeutics, Inc. |
Dll3 binding proteins and methods of use
|
CN113166269A
(zh)
|
2018-11-13 |
2021-07-23 |
指南针制药有限责任公司 |
对抗检查点分子的多特异性结合构建体及其用途
|
AU2019402189B2
(en)
|
2018-12-20 |
2023-04-13 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
KR20210106491A
(ko)
|
2018-12-20 |
2021-08-30 |
노파르티스 아게 |
약제학적 조합물
|
BR112021015783A2
(pt)
|
2019-02-15 |
2021-10-05 |
Novartis Ag |
Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina-2,6-diona e usos dos mesmos
|
BR112021015672A2
(pt)
|
2019-02-15 |
2021-10-05 |
Novartis Ag |
Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona substituída e usos dos mesmos
|
US10871640B2
(en)
|
2019-02-15 |
2020-12-22 |
Perkinelmer Cellular Technologies Germany Gmbh |
Methods and systems for automated imaging of three-dimensional objects
|
WO2020172553A1
(en)
|
2019-02-22 |
2020-08-27 |
Novartis Ag |
Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
|
CN113613676A
(zh)
|
2019-03-19 |
2021-11-05 |
中外制药株式会社 |
包含对抗原的结合活性因mta而变化的抗原结合结构域的抗原结合分子及用于获得该抗原结合结构域的文库
|
BR112021019337A2
(pt)
|
2019-03-29 |
2021-12-07 |
Atarga Llc |
Anticorpo anti-fgf23
|
WO2020254828A1
(en)
|
2019-06-21 |
2020-12-24 |
Vhsquared Limited |
Compositions
|
US20220242945A1
(en)
|
2019-06-21 |
2022-08-04 |
Sorriso Pharmaceuticals, Inc. |
Polypeptides
|
CA3144567A1
(en)
|
2019-06-21 |
2020-12-24 |
Scott Crowe |
Polypeptides
|
EP4048285A1
(en)
|
2019-10-21 |
2022-08-31 |
Novartis AG |
Tim-3 inhibitors and uses thereof
|
IL292347A
(en)
|
2019-10-21 |
2022-06-01 |
Novartis Ag |
Combination treatments with ventoclax and tim-3 inhibitors
|
CN114761037A
(zh)
|
2019-11-26 |
2022-07-15 |
诺华股份有限公司 |
结合bcma和cd19的嵌合抗原受体及其用途
|
JP2023505490A
(ja)
|
2019-12-06 |
2023-02-09 |
アブリンクス・エヌ・フェー |
TNFαおよびOX40Lを標的とする免疫グロブリン単一可変ドメインを含むポリペプチド
|
BR112022009799A2
(pt)
|
2019-12-06 |
2022-08-16 |
Ablynx Nv |
Polipeptídeos compreendendo domínios variáveis únicos de imunoglobulina alvejando tnfalfa e il-23
|
IL293548A
(en)
|
2019-12-09 |
2022-08-01 |
Ablynx Nv |
Polypeptides comprising immunoglobulin with single variable domains targeting 13 il and tsl
|
KR20220116257A
(ko)
|
2019-12-20 |
2022-08-22 |
노파르티스 아게 |
골수섬유증 및 골수이형성 증후군을 치료하기 위한, 데시타빈 또는 항 pd-1 항체 스파르탈리주맙을 포함하거나 또는 포함하지 않는, 항 tim-3 항체 mbg453 및 항 tgf-베타 항체 nis793의 조합물
|
CN115298322A
(zh)
|
2020-01-17 |
2022-11-04 |
贝克顿迪金森公司 |
用于单细胞分泌组学的方法和组合物
|
BR112022012310A2
(pt)
|
2020-01-17 |
2022-09-06 |
Novartis Ag |
Combinação compreendendo um inibidor de tim-3 e um agente hipometilante para uso no tratamento de síndrome mielodisplásica ou leucemia mielomonocítica crônica
|
CA3170833A1
(en)
|
2020-02-21 |
2021-08-26 |
Harpoon Therapeutics, Inc. |
Flt3 binding proteins and methods of use
|
US20230174933A1
(en)
|
2020-02-27 |
2023-06-08 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
US20230136595A1
(en)
|
2020-03-30 |
2023-05-04 |
Ablynx Nv |
Method for the production and purification of multivalent immunoglobulin single variable domains
|
CN115916199A
(zh)
|
2020-06-23 |
2023-04-04 |
诺华股份有限公司 |
包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
|
UY39324A
(es)
|
2020-07-16 |
2022-02-25 |
Novartis Ag |
Anticuerpos anti-betacelulina, sus fragmentos, moléculas de unión multiespecíficas, casetes de expresión, composiciones y métodos de tratamiento.
|
WO2022026592A2
(en)
|
2020-07-28 |
2022-02-03 |
Celltas Bio, Inc. |
Antibody molecules to coronavirus and uses thereof
|
JP2023536164A
(ja)
|
2020-08-03 |
2023-08-23 |
ノバルティス アーゲー |
ヘテロアリール置換3-(1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその使用
|
WO2022043557A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
WO2022043558A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
IL301581A
(en)
|
2020-09-25 |
2023-05-01 |
Ablynx Nv |
Polypeptides comprising single immunoglobulin variable sites targeting 13-IL and OX40L
|
US20240002509A1
(en)
|
2020-11-06 |
2024-01-04 |
Novartis Ag |
ANTIBODY Fc VARIANTS
|
WO2022104061A1
(en)
|
2020-11-13 |
2022-05-19 |
Novartis Ag |
Combination therapies with chimeric antigen receptor (car)-expressing cells
|
EP4256067A2
(en)
|
2020-12-04 |
2023-10-11 |
Tidal Therapeutics, Inc. |
Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
|
EP4263602A1
(en)
|
2020-12-18 |
2023-10-25 |
Ablynx N.V. |
Polypeptides comprising immunoglobulin single variable domains targeting il-6 and tnf-alpha
|
CA3205422A1
(en)
|
2020-12-18 |
2022-06-23 |
Ablynx Nv |
Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor
|
CA3203141A1
(en)
|
2020-12-18 |
2022-06-23 |
Ablynx Nv |
T cell recruiting polypeptides based on tcr alpha/beta reactivity
|
JP2024505049A
(ja)
|
2021-01-29 |
2024-02-02 |
ノバルティス アーゲー |
抗cd73及び抗entpd2抗体のための投与方式並びにその使用
|
CN117321076A
(zh)
|
2021-02-19 |
2023-12-29 |
美国卫生及公众服务部代表 |
中和SARS-CoV-2的单结构域抗体
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
CN113583125B
(zh)
*
|
2021-07-09 |
2022-09-20 |
苏州晟济药业有限公司 |
抗体以及包含其的结合剂、免疫吸附材料及其应用
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
WO2023092004A1
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
WO2023089191A1
(en)
|
2021-11-22 |
2023-05-25 |
Ablynx N.V. |
Obtaining sequence information for target multivalent immunoglobulin single variable domains
|
TW202342508A
(zh)
|
2021-12-17 |
2023-11-01 |
比利時商艾伯霖克斯公司 |
包含靶向TCRαβ、CD33和CD123的免疫球蛋白單可變結構域的多肽
|
WO2023150778A1
(en)
|
2022-02-07 |
2023-08-10 |
Visterra, Inc. |
Anti-idiotype antibody molecules and uses thereof
|
TW202342522A
(zh)
|
2022-03-07 |
2023-11-01 |
日商武田藥品工業股份有限公司 |
臨床人類igg產品之親和層析生產
|
WO2023220695A2
(en)
|
2022-05-13 |
2023-11-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
US20240002331A1
(en)
|
2022-06-08 |
2024-01-04 |
Tidal Therapeutics, Inc. |
Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
|
WO2023242247A1
(en)
|
2022-06-14 |
2023-12-21 |
Ablynx Nv |
Immunoglobulin single variable domains targeting t cell receptor
|
WO2024017915A1
(en)
|
2022-07-18 |
2024-01-25 |
Ablynx N.V. |
Cx3cr1-binding compounds, uses thereof and related methods
|
US20240132624A1
(en)
|
2022-07-27 |
2024-04-25 |
Ablynx N.V. |
Polypeptides binding to a specific epitope of the neonatal fc receptor
|
WO2024030976A2
(en)
|
2022-08-03 |
2024-02-08 |
Voyager Therapeutics, Inc. |
Compositions and methods for crossing the blood brain barrier
|
WO2024068944A1
(en)
|
2022-09-30 |
2024-04-04 |
Sanofi |
Anti-cd28 antibodies
|
WO2024083843A1
(en)
|
2022-10-18 |
2024-04-25 |
Confo Therapeutics N.V. |
Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
|